New Peptide Guides Cancer Vaccines Straight to Lymph Nodes by Targeting a Key Receptor on Immune Cells

The researchers used phage display technology to screen for peptides that bind CCR7, then validated the top candidate (CRBP3) with binding assays on dendritic cells. They tested lymph node accumulation in mice via footpad injection, measured MHC-I complex formation and T cell activation in vitro, and evaluated antitumor efficacy in two mouse tumor models: anti-PD-1-responsive B16-OVA melanoma and anti-PD-1-resistant TC-1 cervical cancer.

Cancer vaccines often fail because antigens don't reach the lymph nodes efficiently. By using a peptide that naturally homes to lymph nodes via CCR7, this approach could make peptide-based cancer vaccines far more potent — and the fact that it worked in an anti-PD-1-resistant tumor model suggests it could complement or even substitute for checkpoint immunotherapy in hard-to-treat cancers.

This work sits at the intersection of peptide engineering and cancer immunotherapy. While checkpoint inhibitors like anti-PD-1 have transformed oncology, many tumors remain resistant. Lymph node-targeted peptide vaccines represent a complementary strategy that could expand the reach of immunotherapy to resistant cancers, and the modular design — swap in any tumor antigen — makes the platform broadly adaptable.

All efficacy data come from mouse tumor models, which don't always predict human outcomes. The study did not evaluate toxicity in detail, and the specific doses and schedules may not translate directly to human use. CCR7 expression patterns on human dendritic cells may differ from mice, potentially affecting targeting efficiency.